With the diversity of existing immunomodulators capable of producing either stimulating or suppressing effect on the immune system, we chose to scientifically investigate the use of transfer factor products in pathological conditions necessitating immunocorrection.

Studies demonstrating the clinical and immunological effectiveness of Transfer Factor and Transfer Factor Plus in the treatment of patients with HIV infection, hepatitis B and C, herpes, urogenital chlamydiosis, severe bacterial infection (osteomyelitis), helminthic invasions (opisthorchiasis), as well as malignant tumors (gastric cancer), dermatoses (psoriasis, atopic dermatitis) and duodenal ulcer were carried out in different clinics of Russian Federation from 2000 through 2003.

The results of the clinical studies, it helped to evaluate the effectiveness and safety, the duration of treatments, the doses of Transfer Factor products and prospects of their use not only in the above mentioned diseases, but in the complex treatment of various pathological conditions.